Internal Medicine, Rheumatology · Hyannis, MA
NPI
1538415526
Since 2012
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
1030 Falmouth Rd
Hyannis, MA, 02601
Phone (774) 470-5080
Groups this clinician bills Medicare through
Medicare paid, 2024
$184K
6,079 services
Medicare patients, 2024
865
Average age 75
Drug cost, 2024
$6.5M
6,115 prescriptions
Company payments, 2025
$3,038
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Krzysztof Rosadzinski was code J1010 (injection, methylprednisolone acetate, 1 mg), 2,250 times for 50 patients. In total Krzysztof Rosadzinski billed 6,079 services in 20 codes, and Medicare paid $184K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-08-26.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 2,250 | 50 | $0.10 | $235 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,149 | 730 | $12.87 | $15K |
| 99214 Office E&M - Established | Office | 1,083 | 637 | $93.96 | $102K |
| 99213 Office E&M - Established | Office | 482 | 384 | $64.04 | $31K |
| 99215 Office E&M - Established | Office | 122 | 114 | $136.74 | $17K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 43 | 42 | $13.09 | $563 |
| 20610 Joint Injection | Office | 37 | 34 | $52.50 | $1,942 |
| J1030 Injection, methylprednisolone acetate, 40 mg | Office | 29 | 24 | $4.17 | $121 |
| 99214 Office E&M - Established | Facility | 27 | 26 | $74.23 | $2,004 |
| 99204 Office E&M - New | Office | 27 | 27 | $95.08 | $2,567 |
| 20600 Joint Injection | Office | 24 | 19 | $50.80 | $1,219 |
| 99212 Office E&M - Established | Office | 21 | 21 | $32.78 | $688 |
| 96372 Injection Administration | Office | 19 | 13 | $11.64 | $221 |
| 99213 Office E&M - Established | Facility | 16 | 16 | $48.98 | $784 |
By year: 2022 $308K for 10,880 services; 2023 $283K for 8,749 services; 2024 $184K for 6,079 services.
Medicare prescription drug claims, 2024
In 2024, the drug Krzysztof Rosadzinski prescribed most often to Medicare patients was Prednisone, with 1,132 prescriptions and refills. In total Krzysztof Rosadzinski wrote 6,115 Medicare prescriptions that cost $6.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 1,132 | 1,390 | 495 | $5,327 |
| Hydroxychloroquine Sulfate Generic | 893 | 1,675 | 227 | $33K |
| Methotrexate Methotrexate Sodium | 600 | 958 | 170 | $11K |
| Methylprednisolone Generic | 286 | 350 | 94 | $4,847 |
| Gabapentin Generic | 245 | 303 | 59 | $2,208 |
| Alendronate Sodium Generic | 241 | 552 | 90 | $1,999 |
| Enbrel Sureclick Etanercept | 178 | 181 | 29 | $1.3M |
| Allopurinol Generic | 177 | 394 | 47 | $1,781 |
| Duloxetine Hcl Generic | 172 | 285 | 58 | $4,105 |
| Famotidine Generic | 169 | 327 | 58 | $1,409 |
| Diclofenac Sodium Generic | 166 | 169 | 79 | $3,454 |
| Humira(Cf) Pen Adalimumab | 162 | 173 | 31 | $1.3M |
| Tramadol Hcl Generic | 146 | 146 | 32 | $830 |
| Tizanidine Hcl Generic | 97 | 157 | 59 | $1,713 |
| Colchicine Generic | 90 | 161 | 29 | $6,085 |
Brand drugs: - claims; generic drugs: 5,041 claims; opioid claims: 258.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Krzysztof Rosadzinski $3,038 ($3,038 in general payments such as food, travel and fees) from 25 companies. The largest payer was Abbvie Inc. with $663.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 37 | $663 |
| Amgen Inc. AMGN | 23 | $411 |
| Mallinckrodt Hospital Products Inc. | 7 | $324 |
| Janssen Biotech, Inc. JNJ | 2 | $245 |
| Vertex Pharmaceuticals Incorporated VRTX | 4 | $208 |
| Genzyme Corporation SNY | 4 | $132 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $119 |
| Novo Nordisk Inc NVO | 5 | $111 |
| UCB, Inc. UCB.BR | 5 | $110 |
| AstraZeneca Pharmaceuticals LP AZN | 4 | $106 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.